Novo Nordisk’s Wegovy (semaglutide, 2.4mg) Receives the US FDA’s Approval for Weight Management in Adults with Obesity

 Novo Nordisk’s Wegovy (semaglutide, 2.4mg) Receives the US FDA’s Approval for Weight Management in Adults with Obesity

Novo Nordisk’s Wegovy (semaglutide, 2.4mg) Receives the US FDA’s Approval for Weight Management in Adults with Obesity

Shots:

  • The approval is based on the results from the P-IIIa STEP clinical trial program evaluating Wegovy (2.4mg injection, qw) in ~4,500 adults with obesity or overweight with at least one weight-related comorbidity
  • Results: the therapy showed 17-18% average weight loss in people without T2D @68wks. and has a safe and well-tolerated profile across the program
  • Wegovy is the first GLP-1 receptor agonist and is expected to launch in the US in Jun’2021. The therapy is currently under regulatory review in the EU and other countries

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Energy Watch

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post